INTRODUCTION
The alkaline phosphatases (EC 3.1.3.1) are intrinsic plasma membrane enzymes found in many tissues. Structural and genetic studies divide the isoenzymes of man into three distinct groups: placental, intestinal (fetal and adult), and hepatic/renal/skeletal (McComb et al., 1979; Seargeant & Stinson, 1979; Moss, 1982) . Liver and bone alkaline phosphatase are thought to be products of the same gene locus but they can be qualitatively distinguished by their different electrophoretic mobility on charge-separation gels and by their different stability to denaturation with heat or urea. These differences in properties are probably due to tissue-specific posttranslational modifications such as glycosylation (Moss & King, 1962; Stinson & Seargeant, 1981; Moss, 1984a) .
Most reported polyclonal antisera raised to either liver or bone isoenzymes show cross-reactivity (McComb et al., 1979) . Soluble forms of liver and bone isoenzymes occur in normal serum, and elevated levels in serum are a feature of certain liver and bone diseases (Moss, 1982 (Moss, , 1984b . Part of the serum alkaline phosphatase of patients with hepatobiliary disease is of high Mr and may be complexed with other plasma membrane enzymes and lipids. High-Mr alkaline phosphatase is diagnostic of obstructive liver diseases, particularly extra-hepatic obstruction (De Broe et al., 1975; Price & Sammons, 1976; Moss, 1982; Siede & Seiffert, 1983) . The origin of high-M, alkaline phosphatase and its relationship with soluble serum enzyme has generated considerable controversy (Price & Sammons, 1974; Crofton & Smith, 1981; De Broe et al., 1985; Kaplan, 1986; Wulkan & Leijnse, 1986; Maguire et al., 1986) .
The aim of the present study was to prepare and use monoclonal antibodies against liver and bone alkaline phosphatase in investigating the nature and extent of differences between these isoenzymes and between tissue and serum forms. In addition it was hoped that the Vol. 244 * Present address: Department of Clinical Biochemistry, John Radcliffe Hospital, Headington, Oxford OX3 9DU, U.K. 725 potential high specificity of monoclonal antibodies could be used in establishing clinically useful assays for particular tissue or serum forms. Initially, six mouse monoclonal antibodies were raised using partiallypurified human liver alkaline phosphatase as antigen (Bailyes et al., 1985) . They all reacted with the same epitope on the enzyme, and cross-reacted with bone alkaline phosphatase. One of the antibodies was chosen for immunoaffinity purification of liver and bone alkaline phosphatases to provide pure antigen for preparing further monoclonal antibodies.
EXPERIMENTAL Materials
Sulphobetaine 14 dimethyl-N-tetradecyl)ammoniopropane-1 -sulphonate] was obtained from Calbiochem. Titan III cellulose acetate was purchased from Helena Lab (U.K.), Unit 2B, Airport Industrial Estate, Kenton, Newcastle-uponTyne, U.K. Assays
Alkaline phosphatase activity was measured at 37°C using 10 mM-4-nitrophenyl phosphate in 0.75 M-2-amino-2-methylpropan-l-ol/HCl buffer, pH 10.3; 1 unit of enzyme activity = 1,umol of substrate hydrolysed/min. Enzyme activity after polyacrylamide-gel electrophoresis was determined by incubating the gels in 1 mg of a-napthyl acid phosphate (Sigma N-7000)/ml in 0.38 MTris/0.5 mM-MgCl2 for 30 min, followed by 1.33 mg of Fast Blue BB (Sigma F-0250)/ml in the above buffer to stain the activity bands. Enzyme activity after cellulose acetate electrophoresis was also determined by this method using an overlay technique, but with 2-amino-2-methylpropan-1-ol/HCl, pH 10.3, as the buffer. 5'-Nucleotidase activity was measured by a continuous monitoring colorimetric method with AMP as substrate (Maguire, 1985) . Protein was measured by the method of Lowry et al. (1951) with bovine serum albumin as standard.
Monoclonal antibodies
Balb/c mice were immunized with liver or bone alkaline phosphatase and monoclonal antibodies to these enzymes were produced as described for the production of antibody 5N4-2 (Siddle et al., 1981) . Culture supernatants were screened for anti-(alkaline phosphatase) antibodies by the enzyme-antigen immunoassay of Jemmerson & Fishman (1982) . Polyvinyl chloride 96-well flexible assay plates (Falcon 3912) were coated with sheep anti-(mouse IgG) antibodies (Siddle et al., 1981) by incubating the wells overnight at 4°C with 150 l1 of 50 mM-potassium phosphate buffer, pH 6.5, containing 0.1 mg of sheep IgG/ml. After washing with 50 mM-Tris/HCl (pH 7.5)/l mM-MgCl2/0.1 % sulphobetaine 14/0.1 % bovine serum albumin (wash buffer), the wells were incubated for 1 h with 100 #u1 of spent culture supernatants and 50,1 of wash buffer. After washing, wells were incubated for 1 h with 100 ,l of liver or bone alkaline phosphatase at 0.1 unit/ml in wash buffer. After further washing, 100,ul of enzyme assay cocktail was added and the plates were incubated at 37 'C. The reaction was stopped by the addition of 50#1d of 2 M-NaOH and the A405 of the wells was determined with an automatic plate-reader (Flow Laboratories; Titertek Multiscan MC). Purification of liver and bone alkaline phosphatase Microsomal membranes were prepared from human liver obtained < 12 h post-mortem and from fetal limb bones < 48 h post mortem. The enzymes were solubilized with 2% (w/v) sulphobetaine 14 and purified to homogeneity on an anti-(alkaline phosphatase) monoclonal antibody immunoadsorbent prepared by coupling the antibody to aminocellulose by diazotization (Hales & Woodhead, 1980) . The enzymes were eluted with fresh 50 mM-diethylamine at 0°C, neutralized with 2 MTris/HCl, pH 6.8, passed down an ACA34 gel filtration column and concentrated using an Amicon PM30 membrane (Bailyes et al., 1982) . Butanol-extracted liver alkaline phosphatase was partially purified by the first three steps of Meyer et al. (1982) before application to the monoclonal antibody immunoadsorbent. The liver was extracted with a 2:1 mix of 10 mM-Tris/HCI (pH 7)/I mM-MgCi2/0.025 mM-ZnCl2 and butan-l -ol and the aqueous phase was applied batchwise to DE-52 cellulose equilibrated in the above buffer. The enzyme was eluted with 0.75 M-NaCl and bound to concanavalin A-Sepharose (Pharmacia). After elution with a-methyl mannoside the enzyme was purified to homogeneity as described for the detergent-solubilized enzyme, except that no detergent was added to the buffers used. Liver membrane preparation A human liver membrane fraction was also prepared by the method described by Cuatrecasas (1972) for rat liver and used to study the binding of membrane-bound and detergent-solubilized liver alkaline phosphatase to the antibody immunoadsorbents. Electrophoresis SDS/polyacrylamide-gel electrophoresis was conducted as previously described (Bailyes et al., 1982) . Gels were stained for protein by the silver stain method of Ansorge (1982) . Non-denaturing polyacrylamide gels were prepared as described previously (Newby et al., 1978) , using buffer system 4229 of Jovin et al. (1970 (Soos & Siddle, 1983; Soos et al., 1986) . The preincubation mixture consisted of spent culture medium or IgG (50 jig of protein/ml) with an equal volume of alkaline phosphatase at 0.1 unit/ml. The antibodies were immobilized by incubating sheep anti-(mouse IgG)-coated wells with either spent culture medium or purified IgG (50,g of protein/ml) and then blocking any excess binding sites with non-specific mouse IgG. 
RESULTS
Immunoaffliity purification and properties of liver and bone alkaline phosphatase Microsomal membranes from human liver and fetal bones were prepared, extracted with sulphobetaine 14 and the alkaline phosphatases immunoaffinity-purified using a previously isolated monoclonal antibody (coded LAP 1/7) to the liver isoenzyme (Bailyes et al., 1985) , as described in the Experimental section. A typical preparation of the liver isoenzyme is shown in Table 1 . After the immunoaffinity step, gel filtration removed minor contaminants, principally immunoglobulin light chains. Omitting gel filtration resulted in a lower specific activity (960 units/mg of protein). Bone alkaline phosphatase was more difficult to prepare than liver alkaline phosphatase. After diethylamine elution and neutralization it was important to change the buffer quickly by using a Sephadex G-25 column, otherwise the activity was unstable. The specific activity obtained in a typical preparation of the pure bone isoenzyme (1091 units/mg of protein) was similar to that of pure liver alkaline phosphatase (1357 units/mg of protein) in agreement with previous reports (Stinson & Seargeant, 1981; Meyer et al., 1982) . Both isoenzymes had an Mr of 80000 determined by SDS/polyacrylamide-gel electrophoresis ( Fig. 1) . On non-denaturing polyacrylamide gels the mobility of the bone isoenzyme was slightly lower than that of the liver isoenzyme (Fig. 2) .
Detergent solubilization or butanol extraction of human liver made no difference to the SDS-gel Mr of the Fig. 1 . SDS/polyacrylaniide-gel electrophoresis of purified bone and liver alkaline phosphatase Sulphobetaine 14-extracted (track a), butanol-extracted liver alkaline phosphatase (track b) and sulphobetaine 14-extracted bone alkaline phosphatase (track c) (2 units of each) were reduced and electrophoresed on a 10% (w/v acrylamide monomer concentration) gel. Track (d), Mr marker proteins (Bio-Rad). The gel was stained for protein by the silver stain method (Ansorge, 1982) .
subsequently immunoaffinity-purified enzyme; both preparations, made from the same liver, gave a single band of Mr 80000 (Fig. 1 ). Upon gel filtration on Ultrogel AcA 34 (the final purification step after elution from the immunoadsorbent), the butanol-extracted enzyme had a smaller apparent Mr. On non-denaturing polyacrylamide gels the butanol-extracted enzyme had a higher mobility, and did not require detergent to enter the restrictive gels. The mobility (RF) of the butanol-and sulphobetaine 14-solubilized liver enzymes over a range of gel concentrations from 7 to 12% (total monomer, w/v) was determined and a Ferguson plot (log RF versus gel concentration) was constructed (Fig. 3) . The slopes of this plot (Kr, the retardation coefficient, a measure of molecular size; Rodbard & Chrambach, 1974) were -0.098 for the butanol-extracted enzyme and -0.11 for the detergent-extracted enzyme. These Kr values can be translated into geometric mean radii of 3.7 nm for the butanol-extracted enzyme (-Mr 168 000) and 4.0 nm for the sulphobetaine 14-extracted enzyme (-= Mr 210000) by linear interpolation from a standard curve as described by Rodbard & Chrambach (1974) . Thus the difference in electrophoretic mobility between the two forms is due to size, not charge, and can probably be accounted for by the binding of the detergent micelle which has an Mr of approx. 30000 (Hjelmeland & Chrambach, 1984 butanol-extracted purified enzyme with sulphobetaine 14 altered their respective electrophoretic mobilities. However, butan6l extraction of liver membranes solubilized with sulphobetaine 14 did convert part of the activity to a mobility corresponding to that of the butanol-extracted purified enzyme (results not shown). In one preparation of sulphobetaine 14-solubilized liver alkaline phosphatase, a small but significant proportion of the purified enzyme had the mobility ofthe butanol-extracted enzyme on non-denaturing polyacrylamide gels (Fig. 2) . In all other preparations, including the portion of liver that was split to provide the sulphobetaine 14-solubilized and butanol-extracted enzyme preparations, only one activity band was seen after detergent extraction. Monoclonal antibodies to alkaline phosphatase Including the previous preparations of six monoclonal antibodies to liver alkaline phosphatase (Bailyes et al., 1985) , three sets of fusions for liver alkaline phosphatase and two sets of fusions for bone alkaline phosphatase were performed, using 12 mice with positive serum titres. In the liver alkaline phosphatase fusions, 137 positive culture supernatants were detected, and in the bone isoenzyme fusions 178 positive culture supernatants. All . Ferguson plot analysis of sulphobetaine 14-extracted and butanol-extracted liver alkaline phosphatase Purified sulphobetaine 14-extracted (@) and butanolextracted (0) liver alkaline phosphatase (30 m-unit each) were electrophoresed on non-denaturing tube gels over the concentration range 7-12% T and stained for alkaline phosphatase activity. The slopes of the two plots were calculated by least-squares linear regression. The mobility of the low-Mr form of the serum enzyme from a patient with cholestasis is also shown (A).
Culture supernatants, from uncloned cells, that had been identified by the binding of liver alkaline phosphatase in the standard screening assay were tested for their ability to discriminate between bone and liver alkaline phosphatase. Both purified enzymes were used at 0.1 unit/ml. The mice were immunized with the liver isoenzyme in fusion (a) and with the bone isoenzyme in fusion (b). The ratio of binding of bone alkaline phosphatase: liver alkaline phosphatase was calculated for each antibody and the resulting ratios were sorted into classes of 0.3-0.49 up to 3.9-4.09 (x axis). The number in each class is shown on the y axis. antibody BAP 1/9 The wells of the plates (Microwell module F-16 high binding capacity; Nunc) were incubated overnight at room temperature in the air flow of a laminar flow cabinet with 100,ul of sheep anti-(mouse IgG) (50 ,g/ml) in 50 mmpotassium phosphate, pH 6.5. Excess binding sites were blocked with bovine serum albumin (5 mg/ml) and the wells were washed with wash buffer. The plates were then incubated with antibody BAP 1/9 at 50 ,sg/ml for 1 h at 20 'C. After two washes, the wells were incubated with the bone isoenzyme (M) or the liver isoenzyme (0) over the concentration range 0.0075-0.2 unit/ml for 1 h. After two further washes, the wells were incubated with enzyme assay cocktail for 40 min at 37 'C and the A405 of the wells was determined on the plate-reader. Each point is the mean of at least four determinations. For all points S.E.M. < 0.008 A405. The slopes of the two plots were calculated by least-squares linear regression and were 3.6 for the bone enzyme and 1.6 for the liver enzyme.
were incubated with equal amounts of enzyme activity of purified liver and bone alkaline phosphatase to determine their specificity. No antibodies totally specific for liver or bone alkaline phosphatase were observed. The profiles of the ratios of binding of bone: liver alkaline phosphatase obtained in a set of liver isoenzyme fusions and bone isoenzyme fusions prior to cloning is shown in Fig. 4 . Most of the antibodies (70%) in the liver fusion (four spleens) displayed a binding ratio of 0.9-1.3, and 70% of the antibodies in the bone fusion (four spleens) displayed a binding ratio of 1.1-1.7. From all the fusions a selection of cells were cloned, providing 27 antibodies together, 15 raised to the liver isoenzyme and 12 raised to the bone isoenzyme. None of these antibodies affected enzyme activity singly or in pairs (results not shown). None showed significant crossreaction with placental or intestinal alkaline phosphatase in the binding assay. Several of the antibodies retained a preference for bone alkaline phosphatase after cloning (nine of them showing at least a 2-fold preference; results not shown). The specificity was tested by coating plates with 5-fold dilutions of culture supernatant (undiluted to 1:3125) and incubating with equal amounts of liver and bone alkaline phosphatase. For some antibodies the apparent preference for bone alkaline phosphatase increased at lower antibody concentrations, e.g. antibodies coded BAP 7B3 and BAP 4A5 increased from a ratio of 1.8 to 3.0 from undiluted to 1:3125 dilution. Other antibodies maintained a fairly constant ratio of bone: liver enzyme binding over the entire concentration range. Ten antibodies (BAP 1/8, 1/9, 1/10, 1/15, 4A5, 4D1, 5A5, 5D4, 7B3; LAP 1/5) were subsequently purified from ascites fluid. All of these antibodies were found to be IgGj, except for BAP 4DI which was IgG2., using a dot immunoblotting assay (Beyer, 1984) . The binding of bone and liver alkaline phosphatase over the concentration range 0.0075-0.2 unit/ml to antibody BAP 1/9 is shown in Fig. 5 . In two separate experiments the ratio of the slope of the bone enzyme plot to that of the liver enzyme plot was 2.25 and 2.1.
Epitope analysis of the monoclonal antibodies (Soos & Siddle, 1983; Soos et al., 1986 ) revealed a complex pattern. Twenty-three antibodies were analysed in one experiment and the binding of liver alkaline phosphatase to monoclonal antibody-coated plates in the presence of soluble antibody, expressed relative to the binding obtained in medium alone, is shown for each antibody (Fig. 6) . Nineteen of these twenty-three antibodies were assigned to six epitope groupings on the basis of their patterns of binding. The remaining four antibodies were difficult to classify, i.e. antibodies coded 5D4, 5A5, LAP 2/35 and LAP 2/50. Antibody LAP 1/7 was classified in other similar experiments into epitope group I and antibodies BAP 1/8, 1/9 and 1/10 similarly into epitope group V. Using bone enzyme for epitope analysis the antibodies could be assigned to the same epitope groupings as with liver enzyme (results not shown). From the epitope analysis it is possible to identify antibodies from different epitope groups that will simultaneously bind to the enzyme, particularly antibodies from groups I and V. However, it should be noted that not all pairs of antibodies from different groups were capable of simultaneous binding to liver alkaline phosphatase. Some antibodies in solution stimulated the binding of enzyme to the solid phase up to 388% of the binding found in medium alone; antibodies coded BAP 1/15, LAP 2/22, LAP 2/49, BAP 3C1, BAP 4D1, were particularly effective at this, giving 50% or more stimulation with six or more different antibodies. The Group I antibodies BAP 4B3, LAP 1/1, LAP 1/5, LAP 1/9, LAP 1/12 and LAP 1/13 were particularly affected when present as the solid phase. This effect was also observed when purified antibodies were used instead of antibodies from culture supernatants. Serum alkaline phosphatase
The reaction with monoclonal antibodies of both highand low-Mr forms of alkaline phosphatase found in serum from cholestatic patients was investigated by Vol. 244 measuring uptake onto monoclonal antibody immunoadsorbents. The high-and low-Mr forms of serum alkaline phosphatase were separated by gel filtration (Fig. 7) . In serum samples from four cholestatic patients 25+7% of alkaline phosphatase and 68+5% of 5'-nucleotidase eluted in the void volume. High-and low-Mr forms of serum alkaline phosphatase were also distinguished as fast-moving and slow-moving forms respectively by cellulose acetate electrophoresis (Fig. 8 ) in agreement with De Broe et al. (1985) . When high-Mr serum alkaline phosphatase was incubated with monoclonal antibody LAP 1/ 12 immunoadsorbent, binding of enzyme activity was 20 + 6% (n = 6) in the absence of detergent and 78 + 6% (n = 6) in the presence of 2% (w/v) sulphobetaine 14. Similar data were observed for the binding of liver membrane fractions; 12 + 8% (n = 6) alkaline phosphatase being bound in the absence of detergent and 82 + 9% (n = 6) in its presence. In contrast, most of the serum low-Mr alkaline phosphatase bound to the immunoadsorbent with [87 + 2% (n = 5)], or without [76 + 5% (n = 5)], detergent treatment. in agreement with the immunoadsorbent binding data, when serum from a patient with obstructive liver disease was reacted with antibody LAP 1/ 12 immunoadsorbent, alkaline phosphatase that was slow-moving during electrophoresis on cellulose acetate was selectively bound relative to the fast-moving form (Fig. 8) .
Further analysis of the binding of high-and low-Mr forms of serum alkaline phosphatase to monoclonal antibodies showed that binding to LAP 3/60 (Group I) and BAP 4A5 (Group II) immunoadsorbents was similar to that observed to the LAP 1/12 immunoadsorbent (Group I) and to an immunoadsorbent prepared from a polyclonal rabbit antiserum to liver alkaline phosphatase (Maguire et al., 1986) . In an experiment with a serum sample from a patient with Paget's disease in which the alkaline phosphatase activity (presumed to be of bone origin) was 2000 units/l, > 99% of the enzyme activity bound to a LAP 1/12 immunoadsorbent.
Investigation of the mobility in polyacrylamide-gel electrophoresis of low-Mr soluble alkaline phosphatase from the sera of patients with obstructive liver disease showed that this enzyme did not E. M. Bailyes and others enter restriction polyacrylamide gels and had a mobility similar to that of butanol-extracted liver membrane enzyme (Fig. 3) .
DISCUSSION
In the present experiments to prepare monoclonal antibodies to alkaline phosphatase, five sets of cell fusions (three for liver enzyme and two for bone) produced 315 positive culture supernatants which cross-reacted with both isoenzymes. Subsequently 27 antibody-producing cell lines were successfully cloned and after preparing ascites fluid nine antibodies were shown to retain at least 2-fold specificity for bone relative to liver alkaline phosphatase. No antibodies specific for liver isoenzyme were obtained. Reaction of the monoclonal antibodies with both isoenzymes was in agreement with previous observations that polyclonal antisera to these isoenzymes usually cross-react (McComb et al., 1979) , although there is a single report ofthe preparation ofa bone-specific polyclonal antiserum using enzyme from a cultured cell line as antigen (Singh & Tsang, 1975) . Nevertheless, it might have been expected that monoclonal antibodies would show greater specificity in view of the observation that alleles of placental alkaline phosphatase having very similar physical properties can be distinguished by monoclonal antibodies (Harris, 1983) . Using bone alkaline phosphatase as antigen a larger percentage of culture supernatants showed some specificity for the bone enzyme compared with using liver alkaline phosphatase as antigen (Fig. 4) . Epitope analysis of the 27 monoclonal antibodies assessed by competitive binding showed a complex pattern of at least six epitope groups. Certain antibody pairs used in solution or solid phase did not show reciprocal effects. A similar situation was observed with monoclonal antibodies prepared to the human insulin receptor (Soos et al., 1986) . In the present study, immunoaffinity-purified liver and bone alkaline phosphatase isoenzymes appeared to be homodimers of Mr-80000 subunits. It is possible that binding of an antibody to one of the subunits may cause conformational changes allowing greater binding of other antibodies, thus accounting for the observation that some antibodies stimulated the binding of the enzyme to others. Epitopes defined by antibody binding to liver alkaline phosphatase appear to be present on bone alkaline phosphatase and antibodies showing some specificity for the bone isoenzyme are present in each epitope group. Recent experiments on the liver isoenzyme using endoglycosidase F suggest that approximately one-third of the apparent Mr can be accounted for by carbohydrate side chains (Garattini et al., 1986) . Differences in the carbohydrate side chains are known to explain some of the different properties of liver and bone alkaline phosphatase isoenzymes, and it is known that neuraminidase treatment abolishes the difference in isoelectric point between them (McKenna et al., 1979) without affecting thermostability (Stinson & Seargeant, 1981) . Tryptic peptide maps of purified bone and liver isoenzymes are very similar. Clearly, differences in carbohydrate side chains may account for differences in the binding of monoclonal antibodies from several epitope groups to the two isoenzymes. In previous studies monoclonal antibodies raised to liver alkaline phosphatase have been reported, 16 showing crossreactivity with bone isoenzyme (Harris, 1983) , one showing some specificity to the bone isoenzyme (Meyer et al., 1982) , and one showing some specificity to the liver isoenzyme (Lawson et al., 1985) . In the latter case a 3-fold preference for liver alkaline phosphatase observed at room temperature increased to a 5-fold preference after incubation for 20 h at 30 'C. Clearly the prospect of an isoenzyme-specific immunoassay for bone or liver alkaline phosphatase based on any of the 27 antibodies in the present study requires careful investigation of binding conditions. Liver alkaline phosphatase is an intrinsic membrane enzyme and solubilization with organic solvents or detergents is required for purification. Whilst the size difference observed in the present study between the native enzyme purified after solubilization in butanol or sulphobetaine 14 was consistent with the size of the detergent micelle, neither agent altered the properties of enzyme purified in the other. The present analysis of immunoaffinity-purified liver alkaline phosphatase confirms that it is a homodimer of two Mr-80000 subunits.
Although the primary structure is unknown, there is some primary sequence homology between liver alkaline phosphatase and the placental isoenzyme (Garattini et al., 1986) , of which the complete amino acid sequence has been inferred from molecular cloning (Millan, 1986) . The primary sequence data suggests that the placental isoenzyme has a large extracellular N-terminal portion, a hydrophobic membrane-anchoring domain and lacks a cytoplasmic tail. Phosphatidylinositol-specific phospholipase C can release alkaline phosphatase from liver cell membranes (Shukla et al., 1980; Chakrabartty & Stinson, 1983) and it has been suggested that this may result from a covalent attachment ofphosphatidylinositol to provide the enzyme's hydrophobic membrane anchor (Low & Zilversmit, 1980; Low et al., 1986 ). An endogenous phospholipase C which can be activated by butanol has been proposed to be responsible both for the butanol-solubilized form of liver alkaline phosphatase and the soluble serum form (Miki et al., 1985) . Our data are consistent with this, since butanol extraction had no effect on the detergent-purified enzyme which does not contain phospholipase C. Also it is of interest to note that a much larger proportion of alkaline phosphatase in the serum of cholestatic patients is present as a soluble rather than a particulate form compared with the enzyme 5'-nucleotidase ( Fig. 7 ; Chuang et al., 1984) . This enzyme, like alkaline phosphatase, is an ectoenzyme with no apparent cytoplasmic tail but is less easily released from the plasma membrane by phosphatidylinositol-specific phospholipase C (Shukla et al., 1980) . There has been controversy over the origin of the high-Mr particulate form of alkaline phosphatase observed in the serum of patients with obstructive liver disease (Kaplan, 1986; Maguire et al., 1986; Wulkan & Leijnse, 1986) . The present experiments show that, when solubilized with the detergent sulphobetaine 14, the enzyme behaves like the soluble serum enzyme both on migration in cellulose acetate electrophoresis and in binding to a variety of immunoadsorbents which also bind to the detergent-solubilized or butanol-extracted purified liver membrane alkaline phosphatase. The data are consistent with both the soluble serum enzyme and particulate enzyme deriving from liver plasma membrane. Whilst we cannot rule out direct shedding from the hepatocyte blood sinusoidal surface (De Broe et al., 1985) , bile regurgitation (Binns et al., 1962) , reverse transcytosis of enzyme released from the bile canalicular surface or enzyme released as a result of disrupted endocytic pathways (Maguire et al., 1986) , it is unlikely that the particulate serum enzyme is a specific bile form (Price & Sammons, 1974) . The inability of the particulate serum enzyme to bind to immunoadsorbents except in the presence of detergent was not unexpected, since the particulate alkaline phosphatase may be present as membrane fragments or micelles in association with other enzymes (De Broe et al., 1975) . It is known that membrane vesicles and fragments can only bind efficiently to immunoadsorbents when indirect techniques are used, in which a membrane-antibody complex is captured on an anti-immunoglobulin immunoadsorbent (Luzio et al., 1976; Richardson & Luzio, 1986) . The selective binding of soluble serum alkaline phosphatase to a monoclonal antibody immunoadsorbent may allow the development of an assay to measure the unbound particulate form of the enzyme in serum. At present there is no simple quantitative method of doing this, yet it has been proposed that the presence of the high-Mr particulate form of alkaline phosphatase in serum is a good indicator of obstructive liver disease (Price & Sammons, 1976; Siede & Seiffert, 1983) .
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